Download Free Medical General principles of pharmacology PowerPoint Presentation

General principles of pharmacology PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Pharmacology, which is titled "General principles of pharmacology", to get yourself acquainted with the general principles of pharmacology.

Tags : Pharmacology, General principles, pharmacology

Published on : Jul 20, 2021 | Views : 2951 | Downloads : 5

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

GENERAL PRINCIPLES OF PHARMACOLOGY Pharmacology is the study drug effects on living systems Most drugs alter central nervous system function by acting at the level of the individual nerve cell
Slide 2-

GENERAL PRINCIPLES OF PHARMACOLOGY The human brain contains approximately 20 billion neurons, each of which may share up to 100,000 synapses (connections) with other neurons Groups of neurons in the brain have specific functions. For example, some are involved with thinking, learning, and memory. Others are responsible for receiving sensory information. Still others communicate with muscles, stimulating them into action
Slide 3-

NEURON PHYSIOLOGY Each neuron has a cell body, an axon, and many dendrites The cell body controls all of the cell's activities The axon extends out from the cell body and transmits messages to other neurons Dendrites also branch out from the cell body. They receive messages from the axons of other nerve cells
Slide 4-

GENERAL PRINCIPLES OF PHARMACOLOGY Modulation of neuronal activity via neurotransmitters (i.e., communication between neurotransmitters) is a fundamental mechanism of brain function The release of neurotransmitters, their mechanisms of action and their effect on target neurons are complex and still poorly understood.
Slide 5-

Mechanisms of Drug Action Drug administration can facilitate or inhibit neurotransmitter systems in the brain in several ways: By altering the synthesis of the neurotransmitter By interfering with the storage of the neurotransmitter By altering the release of the neurotransmitter By interfering with the inactivation of the neurotransmitter (by enzymes or reuptake) By interacting with receptors
Slide 6-

Neurotransmitter Systems gultamatergic GABAergic systems cholinergic serotonergic noradrenergic dopaminergic widely distributed densely packed in circumscribed areas of brain which project to their target areas - lead to more circumscribed effects
Slide 7-

Serotonin Serotonin is linked to many brain functions due to the widespread serotonergic projections and the heterogeneity of the serotonergic receptors Examples include: Modulation of serotonergic receptors and the reuptake site is beneficial in the treatment of anxiety, depression, OCD, and schizophrenia Blockade of serotonin receptors in the area postrema decreases nausea and emesis Hallucinogens, such as LSD, modulate serotonergic neurons via serotonergic autoreceptors
Slide 8-

Norepinephrine Noradrenergic neurotransmission has implications for several brain functions Noradrenergic projections modulate sleep cycles, appetite, mood, and cognition. These functions are typically the targets of antidepressant drugs
Slide 9-

Dopamine Dopamine affects several brain functions primarily by modulation of other neurotransmitter systems Decreased dopaminergic functioning leads to Parkinson=s disease and extrapyramidal side effects Dopaminergic projections are involved in the development of addiction to drugs such as ethanol, cocaine, nicotine and opiates
Slide 10-

GENERAL PRINCIPLES OF PHARMACOLOGY Psychotropic Medication any drug prescribed to stabilize or improve mood, mental status, or behavior includes medications typically classified as antidepressants, antianxiety, etc. includes other medications not typically classified as psychotropic when such medication is prescribed to improve or stabilize mood, mental status or behavior (e.g., carbamazepine is usually an antiepileptic medication but can be prescribed for affective disorders) includes herbal or nutritional substances when such substances are used to stabilize or improve mood, mental status, or behavior
Slide 11-

Classification of Psychoactive Drugs Various ways of doing this By the chemical grouping of the drug (e.g., barbiturates) By the action of the drug (e.g., stimulants, dopamine blockers) By the therapeutic use (e.g., antidepressant, antipsychotic) the most common classification scheme is by therapeutic use
Slide 12-

Names of Drugs Trade, Proprietary or Brand Name usually a Acatchy@ name to emphasize the main function such as Oblivon7 for a sleeping pill trade names written with an initial uppercase letter and often carry the superscript 7 for registered trade name Generic name written with lowercase initial letter and the name is derived from the chemical structure of the drug
Slide 13-

Pharmacokinetics The time course and effects of drugs and their metabolites on the body (what the drug does to the body) absorption distribution biotransformation half-life steady-state concentration excretion
Slide 14-

Pharmacokinetics Absorption the process whereby drug molecules enter the bloodstream affected by the route of administration and the particulars of manufacture, such as the thickness of pill coating, type of filler substance, hardness of tablet Distribution the movement of drug molecules through the bloodstream to the site of action protein-binding affects distribution. The ratio of protein-bound to unbound remains constant, so as unbound molecules pass out of the bloodstream other molecules become unbound
Slide 15-

Pharmacokinetics Biotransformation the changes in the structure of drug molecules characteristically produced by enzymatic action in the liver most drugs are converted into inactive metabolites, but some are changed to an active form. some drugs are not metabolized and pass from the body unchanged Half-life determined by measuring the amount of time required for a given blood level to decline by 50%
Slide 16-

Pharmacokinetics Steady State Concentration the concentration of the drug when the amount administered is equal to the amount eliminated per unit time Excretion the process responsible for the removal of drug molecules and metabolites from the body, usually in the urine. some variables that influence the rate of elimination include genotype, age, drug history, and liver or kidney disease
Slide 17-

Drug Effects when a drug is used therapeutically, the desired action is termed the therapeutic effect the effects of all drugs are dose-dependent the amount of drug that is administered determines both qualitative and quantitative aspects of its effects very low doses - no observable effects high enough doses - toxic reactions
Slide 18-

Side Effects any other action is a side effect side effects may be adverse, beneficial, or innocuous adverse drug reactions include toxic effects due to overmedication common side effects that appear at therapeutic dosages idiosyncratic side effects (e.g., allergic reactions) that are not clearly related to dose side effects vary from mild to life-threatening side effects may develop insidiously over a long period of time or may occur in an idiosyncratic and unpredictable fashion
Slide 19-

Side Effects Behavioral Effects Agitation and Restlessness Sedation Impaired memory Hostility, Disinhibition, Aggression Switch Mania Sleep disturbances Withdrawal Reactions
Slide 20-

Side Effects Cardiovascular Effects hypertensive reaction orthostatic hypotension cardiac conduction delays Endocrine and Metabolic Effects hyperprolactinemia hypothyroidism nephrogenic diabetes insipidus hypercalcemia weight gain
Slide 21-

Side Effects Hematologic Reactions aplastic anemia agranulocytosis leukocytosis eosinophilia benign leukopenia thrombocytopenia Hepatic effects changes in liver functions
Slide 22-

Side Effects Reproductive and Adverse Sexual Effects changes in libido priapism impotence ejaculatory and orgasmic disturbances Renal and Genitourinary System Effects polyuria incontinence and enuresis urinary retention renal failure
Slide 23-

Side Effects Immunologic and Gastrointestinal Effects xerostomia dysphagia (may result in aspiration and asphyxiation) gastroesophageal reflux nausea, vomiting and GI discomfort constipation or abnormal distension diarrhea Convulsive effects
Slide 24-

Side Effects Neuromuscular Effects myoclonus nocturnal myoclonus action (inaction) tremor of upper extremities acute extrapyramidal symptoms (including dystonia, neuroleptic-induced parkinsonism, bradykinesia, akinesia, tremor, and rigidity) akathisia tardive symptoms neuroleptic malignant syndrome
Slide 25-

Side Effects Monitoring Adverse Effects Rating scales general purpose side effect-specific scales General medication strategies to deal with side effects Dosage reduction Drug change Adjunctive medication Drug discontinuation
Slide 26-

Medication Management 3 STAGES BASELINE: collection of medical information and behavioral observations for later comparison with treatment. TITRATION: experimental process of trying different doses or types of medication and evaluating therapeutic response and side effects. MAINTENANCE: periodic monitoring of the child’s functioning on the optimal dose selected during the titration stage. Adjustments in the dose or drug may be made in response to changes in functioning or side effects.
Slide 27-

Medication Management TRIAL PROCEDURES OPEN (NON-BLIND): all those involved with the trial, including the child, parents, teachers, and physician, are aware of the type and dose of medication being used. PLACEBO-CONTROLLED (BLIND): active medication and inactive placebo are identically packaged and those involved are unaware of which is being administered.
Slide 28-

Psychopharmacology for Childhood Behavioral and Developmental Disorders Medication is widely recognized as a key treatment for serious psychopathology and behavior problems in children and adolescents the use of medication in children has dramatically increased in the community the use of these treatments has outstripped current efficacy and safety data
Slide 29-

Child PsychopharmacologyThe Challenge individual differences in treatment response are common resistant cases are common -- treatment-resistance may be more common in youth most of this variability is unexplained
Slide 30-

Role of Medication Medication is a single component of a broad treatment plan Medication is usually considered when behavior interventions have been unsuccessful or the behavior is presumed to be of organic origin The use of medication increases as the number and severity of the individual’s behavior problems increase Medications are often used to treat specific diagnoses as well as specific target symptoms
Slide 31-

Pharmacotherapy Commonly used classes of medications to treat psychiatric and behavior problems include: antipsychotics stimulants antidepressants antimanics anxiolytics antiepileptics selective norepinephrine reuptake inhibitors
Slide 32-

Pharmacotherapy Considerations include: indications effects on behavior side effects effects on learning dosing guidelines
Slide 33-

Stimulants - Indications Attention Deficit Hyperactivity Disorder ADHD with comorbid disorders (including mental retardation, Fragile X Syndrome, Tourette Disorder) Hyperactivity in developmental disorders narcolepsy adjunctive treatment in refractory depression
Slide 34-

Stimulant Medications Stimulant medications are the most studied, most commonly used first-line agents for ADHD treatment Stimulant medications improve: core symptoms: inattention, impulsivity, hyperactivity associated symptoms: cognition, on-task behavior, academic performance, social function, defiance, and aggression Good response in preschoolers, school-age children, adolescents and adults
Slide 35-

Stimulant Medications two primary classes of stimulants amphetamines and methylphenidate (MPH) for ADHD response rate for any one particular stimulant is approx. 70% no predictors of response have been identified all stimulants are generally of comparable efficacy there is significant individual variability in response to a particular stimulant
Slide 36-

Stimulant Medications MPH-based and amphetamine-based stimulants have different effects at the neurotransmitter level MPH inhibits the activity of the presynaptic dopamine transporter protein involved in the reuptake of dopamine from the synaptic cleft Amphetamines have a dual effect – blocks the reuptake of dopamine and norepinephrine through inhibition of the dopamine transporter protein and also causing retrograde release of catecholamines (dopamine and norepinephrine) through the transporter
Slide 37-

Stimulant Medications In the treatment of ADHD: If initial stimulant does not work at the highest feasible dose, then an alternate stimulant should be recommended Sub-optimal responders to a given stimulant may benefit from a trial with an alternate stimulant
Slide 38-

Stimulants - Preparations methylphenidate (Ritalin, Methylin, Metadate) long acting preparations: Ritalin-SR, Ritalin LA, Methylin-ER, Metadate-ER, Metadate-CD, Concerta * Methylin comes in an liquid and chewable tablet form dexmethylphenidate (Focalin) long acting preparation: Focalin XR dextroamphetamine (Dexedrine, Dextrostat) long acting preparation: Dexedrine spansules mixed amphetamine salts products (Adderall) long acting preparation: Adderall XR pemoline (Cylert)
Slide 39-

Stimulants - Side Effects most side effects are transient and dose dependent common side effects include: insomnia, decreased appetite, mild increase in heart rate and BP, weight loss, headache, nausea rare side effects include: behavioral rebound, psychosis, anxiety or depression dexmethylphenidate (Focalin) may have fewer side effects than MPH pemoline: liver toxicity
Slide 40-

Concerta Oros delivery system Immediate release of MPH in overcoat of the tablet (22%) followed by progressive 8-hour release by an osmotic pump from 2 separate drug subcompartments (78%) with increasing concentration of medication in the afternoon Designed to mimic TID IR MPH with a 12 hour duration 18, 27, 36, and 54 mg tablets 72 mg tablets may be available soon
Slide 41-

Ritalin LA biphasic release bead technology using SODAS (spheroidal oral drug absorption system) designed to mimic BID MPH 50% immediate release / 50% delayed release bimodal release profile has smoother peaks and troughs compared to BID IR Ritalin 10, 20, 30, and 40 mg capsules can be sprinkled same side effect profile as IR Ritalin designed for 9-hour duration of efficacy
Slide 42-

Metadate CD Biphasic bead technology (Diffucaps) 30% immediate release / 70% delayed release (20 mg capsule = 6 mg initial / 14 mg delayed release) dispensed as a 30-capsule dose pack (6 rows of 5 tablets) 10, 20 and 30 mg capsule designed for 9 hour duration of action Metadate ER is a “branded generic” version of Ritalin SR with wax matrix tablet design
Slide 43-

Adderall XR Longer acting version of Adderall with Microtrol two-bead delivery system 50% immediate release and 50% delayed release designed to parallel 4-hr BID Adderall dosing but duration of action may extend beyond 8 hours (10-12 hours) capsules can be sprinkled (6 dosing sizes available: 5, 10, 15, 20, 25, 30 mg capsules )
Slide 44-

Focalin newest stimulant preparation to be approved by the FDA dexmethylphenidate – d-isomer of MPH d-isomer is clinically active l-isomer is rapidly metabolized and degraded after oral administration and has little, if any, pharmacologic activity short acting immediate release formulation with approx. 5 hr duration of action reportedly “smoother” response than MPH with fewer side effects (esp. insomnia)
Slide 45-

Focalin XR long-acting preparation of dexmethylphenidate recently approved by the FDA (May, 2005) for adults, adolescents, and children available in a capsule form with the SODAS technology
Slide 46-

Methylphenidate Patch transdermal patch designed to be applied once daily MPH not subject to first-pass metabolism in the liver dose can be altered by changing the size of the patch duration of action controlled by removing the patch which stops delivery of the medication
Slide 47-

Long-Acting Stimulant Preparations
Slide 48-

Time (h) 0 5 10 15 0 5 10 15 20 Mean d,l-methylphenidate plasma levels (ng/mL) Comparison of Extended-release Methylphenidate Dosage Forms Gonzalez MA, et al. Int J Clin Pharmacol Ther. 2002;40:175-184. Data on file, Novartis Pharmaceuticals.
Slide 49-

Selective Norepinephrine Reuptake Inhibitor Atomoxetine (Strattera) Highly selective blockade of the presynaptic norepinephrine transporter (relatively more plentiful in the prefrontal cortex than the striatum) Increased concentration of norepinephrine in the anterior and posterior brain attentional systems Downstream increase in dopamine in the prefrontal cortex Does NOT increase the concentration of dopamine in the nucleus accumbens (abuse potential) or striatum (tics)
Slide 50-

Selective Norepinephrine Reuptake Inhibitor Atomoxetine (Strattera) Safety data diastolic BP and heart rate increase in a statistically but not clinically significant manner 20% with decreased appetite - weight decreased in first 9-12 weeks of treatment, then begins to catch up and parallel growth curve no significant lab or EKG changes no exacerbation of tics or anxiety insomnia not a significant side effect *** need to watch for abnormal liver function *** black box warning – may increase suicidal thoughts
Slide 51-

Selective Norepinephrine Reuptake Inhibitor Atomoxetine (Strattera) Several studies showed that once daily dosing strategy similar to twice-daily dosing Atomoxetine associated with improved evening and early morning parent ratings – single daily dose Non-controlled substance First non-stimulant, FDA approved medication for treatment of ADHD in children, adolescents and adults (November, 2002) May take up to 2-4 weeks to see optimal benefit
Slide 52-

Antidepressants - Indications major depressive disorder enuresis ADHD anxiety disorders (e.g., school phobia, separation anxiety, panic disorder, and obsessive-compulsive disorder) sleep disorders (night terrors) some cases of self-injury in individuals with developmental disabilities
Slide 53-

Classes of Antidepressants Tricyclics amitriptyline (Elavil) desipramine (Norpramin) imipramine (Tofranil) nortriptyline (Pamelor) Monoamine Oxidase Inhibitors (MAOIs) phenelzine (Nardil) tranylcypromine (Parnate) Selective Serotonin Reuptake Inhibitors (SSRIs) fluoxetine (Prozac) fluvoxamine (Luvox) paroxetine (Paxil) sertraline (Zoloft) citalopram (Celexa) escitalopram (Lexapro) Others bupropion (Wellburtin) trazodone (Desyrel) venlafaxine (Effexor) nefazodone (Serzone) Mirtazapine (Remeron)
Slide 54-

Tricyclic Antidepressants Side Effects Common: dry mouth, constipation, blurred vision, weight gain, sedation, mild liver and blood count changes Rare: arrhythmias or tachycardia, induction of psychosis or mania ** SLOWING OF CARDIAC CONDUCTION (baseline and maintenance EKG monitoring is required) Contraindicated in patients with cardiac conduction disturbances Sudden discontinuation of the medication may result in flu-like symptoms, an increase in behavioral problems or insomnia
Slide 55-

Antidepressants - Side Effects MAOIs: changes in blood pressure, weight gain, need to follow dietary restrictions SSRIs: irritability, headaches, insomnia, nervousness, drowsiness or fatigue, anorexia, nausea, or diarrhea (safer side effect profile, especially reduced risks of cardiotoxicity and lethality of overdose, compared to tricyclics) bupropion: irritability, insomnia, drug induced seizures (with high doses) trazodone: changes in blood pressure, sexual dysfunction ** recent concerns regarding antidepressants and increased risk for suicidal ideation in children/adolescents
Slide 56-

Antipsychotics - Indications psychotic disorders schizophrenia (exacerbations and maintenance) mania (in conjunction with a mood stabilizer) behavior disorders with severe agitation, aggressivity, and self-injury dyskinetic movement disorders (e.g., Tourette disorder)
Slide 57-

Antipsychotics Traditional antipsychotics Low potency: chlorpromazine (Thorazine) thioridazine (Mellaril) Intermediate potency: loxapine (Loxitane) High potency: haloperidol (Haldol) thiothixene (Navane)
Slide 58-

Antipsychotics New or Atypical Antipsychotics clozapine (Clozaril) risperidone (Risperdal) olanzapine (Zyprexa) quetiapine (Seroquel) ziprasidone (Geodon) aripiprazole (Abilify) - DOPAMINE PARTIAL AGONIST
Slide 59-

Antipsychotics - Side Effects Traditional antipsychotics dystonia anticholinergic effects akasthesia tardive dyskinesia sedation endocrine disturbances confusion malignant neuroleptic syndrome Atypical antipsychotics Clozapine: risk of agranulocytosis
Slide 60-

Antipsychotics - Side Effects
Slide 61-

Antimanics lithium carbonate (Lithobid, Eskalith) indications: manic episodes of bipolar disorder unipolar depression/adjunct treatment in major depressive disorder behavior disorders with extreme agitation or aggression
Slide 62-

Antimanics - Side Effects sedation, confusion electrolyte imbalances gastrointestional distress renal dysfunction
Slide 63-

Classes of Anxiolyics Benzodiazepines alprazolam (Xanax) diazepam (Valium) lorazepam (Ativan) Antihistamines diphenhydramine (Benadryl) hydroxyzine (Atarax) Atypical anxiolytics buspirone (BuSpar)
Slide 64-

Anxioltyics - Indications anxiety disorders seizure control night terrors and sleepwalking acute management of severe agitation adjunct treatment in mania and refractory psychosis Tourette disorder
Slide 65-

Anxioltyics - Side Effects headache sedation and decreased cognitive performance behavior disinhibition gastrointestinal distress physical and psychological dependence (long-acting benzodiazepines) rebound or withdrawal reactions (short-acting benzodiazepines) blood abnormalities anticholinergic effects
Slide 66-

Antiepileptics carbamazepine (Tegretol) Ethosuximide (Zarontin) sodium valproate (Depakote) oxcarbazepine (Trileptal) topiramate (Topamax) gabapentin (Neurontin) lamotrigine (Lamictal)
Slide 67-

Antiepileptics - Indications seizure control bipolar disorder adjunct treatment in major depressive disorder severe behavior problems
Slide 68-

Antiepileptics - Side Effects sedation behavioral disinhibition, overexcitement blood abnormalities anticholinergic effects
Slide 69-

Alpha-Adrenergic Agonists These centrally acting antihypertensive agents have more recently been reported as alternative or adjunctive treatments for: ADHD Tourette disorder behavior disorders with severe agitation, self-injury, or aggression adjunctive treatment of schizophrenia and mania
Slide 70-

Alpha-Adrenergic Agonists Clonidine (Catapres) most common side effect is sedation other side effects include: hypotension other cardiovascular effects headache and dizziness stomach ache, nausea, vomiting available in a skin patch
Slide 71-

Alpha-Adrenergic Agonists Guanfacine (Tenex) much more binding specificity than clonidine most common side effects are: lethargy (60%) insomnia (30%) headache (40%) dizziness (20%)
Slide 72-

Drug Combinations although it is not uncommon in clinical practice, there are few reports in the literature concerning the simultaneous use of more than one medication usually considered in treatment-resistant patients patients with comorbid diagnoses use of two different medications may permit lower doses of each and decrease the potential for side effects further research is needed evaluating the overall safety and efficacy of various drug combinations